One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Lyme Disease Treatment Market

ライム病治療市場市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2028年


[ 英語タイトル ] Lyme Disease Treatment Market by Treatment Type (Medication and Tick Removal), Administration Route (Oral, Injectable, and Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021-2028


Product Code : RDHC00116268
Survey : Research Dive
Publish On : December, 2021
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5700 / Question Form
5 User USD8700 / Question Form
Enterprise User USD10700 / Question Form
Galaxo SmithKline Plc, Pfizer, Inc., Novartis AG, Mayne Pharma, Sun Pharmaceuticals Industries, Inc., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc, Chartwell Pharmaceuticals, and Almirall, LLC.

[Report Description]

According to Research Dive analysis, the global lyme disease treatment market is estimated to generate a revenue of $1,062,794.78 thousand by 2028, increasing from $ 619,692.31 thousand in 2020, at a noteworthy CAGR of 7.50%.

COVID-19 Impact on Lyme Disease Treatment Market
Prevalence of corona virus pandemic has caused negative impact on Lyme disease treatment market. Due to high transmission rate of COVID-19, patients suffering from other diseases such as Lyme disease refrained themselves from visiting doctors and hospitals. This factor has decreased the Lyme disease market share considerably. Also, continuous increasing number of corona patients, worldwide, has forced the healthcare professionals to focus on corona patients and postpone other outpatient visits. This factor is also expected to hinder the market growth.
Lyme Disease Treatment Market Analysis:
Rising prevalence of chronic Lyme disease, worldwide, is expected to drive the market of Lyme disease treatment in the coming years. Lyme disease is caused by a bacteria called Borrelia burgdorferi and is transmitted to humans by the bite of black legged ticks. The number of cases for Lyme disease is increasing as a result of which the demand for proper treatment is also rising rapidly. This factor is expected to raise Lyme disease market share in the forecast time period.
However, as the disease has symptoms like rashes, fever, and body ache, which are also common for other diseases, many healthcare professionals misdiagnose it and prescribe some other medicines. Thus, this factor hinders the market growth of Lyme disease market considerably.
Constant efforts made by the researchers and the scientists to develop a proper vaccine for Lyme cure is anticipated to provide tremendous opportunity for the market players to develop their product portfolio. The companies have engaged their research and development team in research project to develop a proper vaccine for Lyme disease. This factor is likely to generate a good revenue for the market in the future.
Based on treatment type, the Lyme disease treatment market is segmented into medication and tick removal.
The medication sub-segment is predicted to have a dominating market share in the global market and register a revenue of $807,760.80 thousand during the forecast period.
Based on administration route, the global Lyme disease treatment market is segmented into oral, injectable, and topical.
Injectable sub-segment is anticipated to have the fastest market growth and it is predicted that the market shall generate a revenue from $332,571.67 thousand in 2028.

Based on distribution channel, the global Lyme disease treatment market is segmented into hospital pharmacies, retail pharmacies, and online.
The hospital pharmacies sub-segment is predicted to have a dominating Lyme disease treatment market share in the global market and register a revenue of $565,642.08 thousand during the forecast period.
Based on geographical scope, the market was investigated across North America, Europe, Asia-Pacific, and LAMEA. The North America Lyme disease treatment market accounted $ 398,462.15 thousand in 2020 and is projected to register a revenue of $661,058.35 thousand by 2028.
The companies involved in the lyme disease treatment market are Galaxo SmithKline Plc, Pfizer, Inc., Novartis AG, Mayne Pharma, Sun Pharmaceuticals Industries, Inc., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc, Chartwell Pharmaceuticals, and Almirall, LLC.

CHAPTER 1:INTRODUCTION

1.1.Research methodology

1.1.1.Desk research
1.1.2.Real-time insights and validation
1.1.3.Forecast model
1.1.4.Assumptions & forecast parameters

1.1.4.1.Assumptions
1.1.4.2.Forecast parameters

CHAPTER 2:EXECUTIVE SUMMARY

2.1.380° summary
2.2.Treatment types trend
2.3 Administration Route
2.4 Distribution Channel

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key takeaways

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.2.2.1.Top winning strategies, by year
3.2.2.2.Top winning strategies, by development
3.2.2.3.Top winning strategies, by company

3.3.Porter's five forces analysis
3.4.Market dynamics
3.5.Drivers
3.6.Restraints
3.7.Opportunities
3.8.Technology landscape
3.9.Regulatory landscape
3.10.Patent landscape
3.11.Market value chain analysis
3.12.Strategic overview

CHAPTER 4:IMPACT OF COVID19 ON GLOBAL LYME DISEASE TREATMENT MARKET

4.1.Introduction
4.2.COVID-19 health assessment
4.3.Impact of COVID-19 on the global economy
4.4.Impact of COVID-19 on global lyme disease treatment market

4.4.1.Technological impact
4.4.2.Investment scenario

4.5.Lyme disease treatment market size and forecast, by region, 2028-2033

CHAPTER 5:GLOBAL LYME DISEASE TREATMENT MARKET, BY TREATMENT TYPE

5.1.Overview

5.1.1.Market size and forecast, by treatment type

5.2.Medication

5.2.1.Key market trends, growth factors and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market share analysis, by country

5.3.Tick Removal

5.3.1.Key market trends, growth factors and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market share analysis, by country

CHAPTER 6:GLOBAL LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE

6.1.Overview

6.1.1.Market size and forecast, by administration route

6.2.Oral

6.2.1.Key market trends, growth factors and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market share analysis, by country

6.3.Injectable

6.3.1.Key market trends, growth factors and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market share analysis, by country

6.4.Topical

6.4.1.Key market trends, growth factors and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market share analysis, by country

CHAPTER 7:GLOBAL LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

7.1.Overview

7.1.1.Market size and forecast, by distribution channel

7.2.Hospital Pharmacies

7.2.1.Key market trends, growth factors and opportunities
7.2.2.Market size and forecast, by region
7.2.3.Market share analysis, by country

7.3.Retail Pharmacies

7.3.1.Key market trends, growth factors and opportunities
7.3.2.Market size and forecast, by region
7.3.3.Market share analysis, by country

7.4.Online

7.3.1.Key market trends, growth factors and opportunities
7.3.2.Market size and forecast, by region
7.3.3.Market share analysis, by country

CHAPTER 8:GLOBAL LYME DISEASE TREATMENT MARKET, BY REGION

8.1.Overview

8.1.1.Market size and forecast, by region

8.2.North America

8.2.1.Key market trends, growth factors, and opportunities
8.2.2.Market size and forecast, by treatment type
8.2.3 Market size and forecast, by administration route
8.2.4. Market size and forecast, by distribution channel
8.2.5.Market size and forecast, by country

8.2.6.U.S.

8.2.4.1.Market size and forecast, by treatment type
8.2.4.2.Market size and forecast, by administration route
8.2.4.3.Market size and forecast, by distribution channel

8.2.7.Canada

8.2.5.1.Market size and forecast, by treatment type
8.2.5.2.Market size and forecast, by administration route
8.2.5.3.Market size and forecast, by distribution channel

8.2.8.Mexico

8.2.6.1.Market size and forecast, by treatment type
8.2.6.2.Market size and forecast, by administration route
8.2.6.3.Market size and forecast, by distribution channel

8.3.Europe

8.3.1.Key market trends, growth factors, and opportunities
8.3.2.Market size and forecast, by treatment type
8.3.3.Market size and forecast, by administration route
8.3.4.Market size and forecast, by distribution channel

8.3.5.Market size and forecast, by country
8.3.6.Germany

8.3.6.1.Market size and forecast, by treatment type
8.3.6.2.Market size and forecast, by administration route
8.3.6.3.Market size and forecast, by distribution channel

8.3.7.UK

8.3.7.1.Market size and forecast, by treatment type
8.3.7.2.Market size and forecast, by administration route
8.3.7.3.Market size and forecast, by distribution channel

8.3.8.France

8.3.8.1.Market size and forecast, by treatment type
8.3.8.2.Market size and forecast, by administration route
8.3.8.3.Market size and forecast, by distribution channel

8.3.9.Spain

8.3.9.1.Market size and forecast, by treatment type
8.3.9.2.Market size and forecast, by administration route
8.3.9.3.Market size and forecast, by distribution channel

8.3.10.Italy

8.3.10.1.Market size and forecast, by treatment type
8.3.10.2.Market size and forecast, by administration route
8.3.10.3.Market size and forecast, by distribution channel

8.3.11.Rest of Europe

8.3.11.1.Market size and forecast, by treatment type
8.3.11.2.Market size and forecast, by administration route
8.3.11.3.Market size and forecast, by distribution channel

8.4.Asia-Pacific

8.4.1.Key market trends, growth factors, and opportunities
8.4.2.Market size and forecast, by treatment type
8.4.3 Market size and forecast, by administration route
8.4.4.Market size and forecast, by distribution channel
8.4.5.Market size and forecast, by country

8.4.6.China

8.4.6.1.Market size and forecast, by treatment type
8.4.6.2.Market size and forecast, by administration route
8.4.6.3.Market size and forecast, by distribution channel

8.4.7.Japan

8.4.7.1.Market size and forecast, by treatment type
8.4.7.2.Market size and forecast, by administration route
8.4.7.3.Market size and forecast, by distribution channel

8.4.8.India

8.4.8.1.Market size and forecast, by treatment type
8.4.8.2.Market size and forecast, by administration route
8.4.8.3.Market size and forecast, by distribution channel

8.4.9.South Korea

8.4.9.1.Market size and forecast, by treatment type
8.4.9.2.Market size and forecast, by administration route
8.4.9.3.Market size and forecast, by distribution channel

8.4.10.Australia

8.4.10.1.Market size and forecast, by treatment type
8.4.10.2.Market size and forecast, by administration route
8.4.10.3.Market size and forecast, by distribution channel

8.4.11.Rest of Asia-Pacific

8.4.11.1.Market size and forecast, by treatment type
8.4.11.2.Market size and forecast, by administration route
8.4.11.3.Market size and forecast, by distribution channel

8.5.LAMEA

8.5.1.Key market trends, growth factors, and opportunities
8.5.2.Market size and forecast, by treatment type
8.5.3 Market size and forecast, by administration route
8.5.4. Market size and forecast, by distribution channel
8.5.5.Market size and forecast, by country

8.5.6.Latin America

8.5.6.1.Market size and forecast, by treatment type
8.5.6.2.Market size and forecast, by administration route
8.5.6.3.Market size and forecast, by distribution channel

8.5.7.Middle East

8.5.7.1.Market size and forecast, by treatment type
8.5.7.2.Market size and forecast, by administration route
8.5.7.3.Market size and forecast, by distribution channel

8.5.8.Africa

8.5.8.1.Market size and forecast, by treatment type
8.5.8.2.Market size and forecast, by administration route
8.5.8.3.Market size and forecast, by distribution channel

CHAPTER 9:COMPANY PROFILES

9.1.Galaxo SmithKline Plc.

9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Product portfolio
9.1.4.Business performance
9.1.5 Key Strategic moves and development

9.2.Pfizer, Plc.

9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business Segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments

9.3.Novartis AG

9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business Segments
9.3.4.Product portfolio
9.3.5.Business performance
9.3.6.Key strategic moves and developments

9.4.Mayne Pharma

9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Product portfolio
9.4.4. Business performance
9.4.5. Key strategic moves and developments

9.5.Sun Pharmaceuticals Industries, Inc.

9.5.1.Company overview
9.5.2.Company snapshot
9.5.3 Operating segments
9.5.4.Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments

9.6.Lupin Pharmaceuticals Plc.

9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.6.6.Key strategic moves and developments

9.7.Orion Pharmaceuticals

9.7.1.Company overview
9.7.2.Company snapshot
9.7.3 Operating segments
9.7.4.Product portfolio
9.7.5.Business performance
9.7.6 Key strategic moves and developments

9.8.Perrigo Company Plc.

9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business Segments
9.8.4.Product portfolio
9.8.5.Business performance
9.8.6.Key strategic moves and developments

9.9.Chartwell Pharmaceuticals

9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.9.6.Key strategic moves and development

9.10.Almarial LLC

9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
9.10.6.Key strategic moves and developments

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+